dioleoylphosphatidylserine | 4474-63-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: dioleoylphosphatidylserine
• 英文别名: 1,2-Dioleyl-sn-glycero-3-phospho-DL-serin；2-amino-3-[2,3-bis[[(Z)-octadec-9-enoyl]oxy]propoxy-hydroxyphosphoryl]oxypropanoic acid
• CAS: 4474-63-9
• 化学式: C₄₂H₇₈NO₁₀P
• 分子量: 788.056
• InChiKey: WTBFLCSPLLEDEM-CLFAGFIQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.2
• 重原子数：
  54
• 可旋转键数：
  42
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  172
• 氢给体数：
  3
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  柠康酸酐 、 dioleoylphosphatidylserine 在 2,6-二甲基吡啶 作用下， 以 氯仿 为溶剂， 反应 48.0h， 以78%的产率得到N-citraconyl-dioleoylphosphatidylserine
  参考文献：
  名称：

  Synthesis and characterization of N-acylated, pH-sensitive ‘caged’ aminophospholipids

  摘要：

  A series of acid-labile 'caged' phosphatidylserine (PS) and phosphatidylethanolamine (PE) molecules have been synthesized by N-acylation of the aminophospholipid with maleic, citraconic, dimethylmaleic, phthalic, or 3,4,5,6-tetrahydrophthalic anhydride. N-citraconyl-dioleoylphosphatidylethanol (C-DOPE) and N-citraconyl-dioleoylphosphatidylserine (C-DOPS) exhibited the highest degree of sensitivity to acidic pH; incubation at pH 5.5 and 6.5, respectively, resulted in 50% cleavage to the native aminophospholipid within 60 min. Significant cleavage of the phthalyl- and maleyl-PE derivatives did not occur at physiologically relevant pH values (pH 5.5-8), while tetrahydrophthalyl-PE and dimethylmaleyl-PE could not be isolated, reflecting their inherent instability, At pH 5.5, the half time for cleavage of C-DOPE and C-DOPS was 110 min and 85 min, respectively. The utility of these 'caged' lipids was demonstrated in human erythrocytes. When mixed with cells, C-DOPS, or the short chain analog, N-citraconyl-dilauroylphosphatidylserine (C-DLPS), transferred from liposome membranes into erythrocytes and remained in the cell outer monolayer. Low pH treatment released the citraconyl group and the free PS was transported to the inner monolayer by the aminophospholipid transporter. These novel 'caged' phospholipids may be useful for the study of transmembrane aminophospholipid transport, protein-lipid interactions and membrane fusion.

  DOI：

  10.1016/0009-3084(94)02398-o

文献信息

• IMPROVED PROMOTERS AND COMPOSITIONS
  申请人：Oxford University Innovation Limited

  公开号：EP3423579A1

  公开（公告）日：2019-01-09
• COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS
  申请人：Nal Pharmaceutical Group Limited

  公开号：EP3672618A1

  公开（公告）日：2020-07-01
• NANOTUBE TRANS-MEMBRANE CHANNELS MIMICKING BIOLOGICAL PORINS
  申请人：Zhang Jianfei

  公开号：US20170304447A1

  公开（公告）日：2017-10-26

  Provided herein is a nanopore structure, which in one aspect is a “carbon nanotube porin”, that comprises a short nanotube with an associated lipid coating. Also disclosed are compositions and methods enabling the preparation of such nanotube/lipid complexes. Further disclosed is a method for therapeutics delivery that involves a drug delivery agent comprising a liposome with a NT loaded with a therapeutic agent, introducing the therapeutic agent into a cell or a tissue or an organism; and subsequent release of the therapeutic agents into a cell.
• PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE
  申请人：PellFiCure Pharmaceuticals, Inc.

  公开号：US20180221306A1

  公开（公告）日：2018-08-09

  Disclosed herein are pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione. Also disclosed are methods of treating diseases and/or conditions associated with a cancer, such as prostate cancer with such pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione. The disclosed pharmaceutical compositions may provide improved dosage for oral administration to patients in the clinic. The disclosed pharmaceutical compositions may provide improved stability and/or shelf life.
• [EN] COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS<br/>[FR] COMPOSITIONS ET MÉTHODES D'ADMINISTRATION D'AGENTS PHARMACOLOGIQUES
  申请人：NAL PHARMACEUTICAL GROUP LTD

  公开号：WO2019040282A1

  公开（公告）日：2019-02-28

  Nanoparticles and microspheres are provided for delivering an anticancer agent or other active agents to a subject. The nanoparticles and the microspheres are formed from a core that is encased by a coating or shell that includes a somatostatin-albumin fusion protein or analogue thereof. The somatostatin-albumin fusion protein includes at least one albumin (or an analog thereof) moiety, at least one somatostatin moiety (e.g. SST-14, SST-28), and at least one spacer connecting albumin to albumin, somatostatin to somatostatin and/or albumin to somatostatin moieties.